US Patents for PCT: WO2012/151451
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharms Inc | AQVESME | mitapivat sulfate | TABLET;ORAL | 216196-004 | Dec 23, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR INCREASING RED BLOOD CELL LONGEVITY IN ADULTS WITH ALPHA OR BETA THALASSEMIA | ||||
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-001 | Feb 17, 2022 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY | ||||
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-002 | Feb 17, 2022 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY | ||||
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-003 | Feb 17, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
